ONC vs. ROIV: BeOne Medicines vs. Roivant Sciences Stock Comparison

November 11, 2026

How do BeOne Medicines (ONC) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BeOne Medicines (ONC) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Roivant Sciences (ROIV) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Profile Item	ONC	ROIV
Name	BeOne Medicines Ltd. American Depositary Shares	Roivant Sciences Ltd.
Country/Region	Switzerland	United Kingdom
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	46.49 billion USD	28.08 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	February 3, 2016	December 8, 2020
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

ONC

ROIV

GSPC

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BeOne Medicines (ONC) and Roivant Sciences (ROIV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BeOne Medicines (ONC) and Roivant Sciences (ROIV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
Total Return (1Y)	30.59%	96.75%
Total Return (3Y, Annualized)	30.15%	68.04%
Total Return (5Y, Annualized)	2.48%	36.73%

Risk Profile

Drawdown History

ONC

ROIV

GSPC

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BeOne Medicines (ONC) and Roivant Sciences (ROIV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
Volatility (1Y, Annualized)	35.90%	47.99%
Beta (5Y)	0.59	1.17
Max Drawdown (5Y)	-68.89%	-79.22%
Avg. Volume (3M)	405.29K	7.82M

Risk-Adjusted Performance

Risk-Return Positioning

ONC and ROIV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
Sharpe Ratio (1Y)	0.73	1.93
Sortino Ratio (1Y)	1.15	4.03

Profitability

ROE (TTM)

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile BeOne Medicines (ONC) reports 18.40%, ranking against industry peers normally.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.40%

Max: 109.18%
ONC: 18.40%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max: 109.18%
Q3: 6.23%
ROIV: -8.52%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BeOne Medicines (ONC) at 13.86% retains a top-quartile share of revenue as profit, ahead of Roivant Sciences (ROIV) at 0.00%, which keeps about the industry-typical share.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.86%

Max: 18.05%
ONC: 13.86%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
ROIV: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BeOne Medicines (ONC) reports 22.15%, ranking against industry peers normally.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.15%

Max: 83.12%
ONC: 22.15%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
ROIV: -25,408.11%

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
ROE (TTM)	18.40%	-8.52%
ROA (TTM)	8.42%	-16.28%
Net Margin (TTM)	13.86%	0.00%
Operating Margin (TTM)	22.15%	-25,408.11%
Gross Margin (TTM)	89.39%	0.00%

Growth

Revenue Growth

BeOne Medicines (ONC) at 40.23% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BeOne Medicines (ONC) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
Revenue Growth (YoY)	40.23%	-71.57%
Revenue Growth (3Y CAGR)	55.69%	-36.01%
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.55

Max: 25.13
Q3: 12.13
Median: 5.52
ONC: 3.55
Q1: 2.47
Min: 0.10

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max: 25.13
ROIV: 16.72
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both BeOne Medicines (ONC) at 0.35 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.35

Max: 1.42
Q3: 0.65
ONC: 0.35
Median: 0.15
Q1: 0.02
Min: 0.00

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
ROIV: 0.02
Q1: 0.02
Min: 0.00

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
Current Ratio (MRQ)	3.55	16.72
Debt / Equity (MRQ)	0.35	0.02
Net Debt / EBITDA	-2.80	--

Dividends

Dividend Yield (TTM)

Neither BeOne Medicines (ONC) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ONC: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BeOne Medicines (ONC) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ONC: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: BeOne Medicines (ONC) trades at 52.17 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.17

Max: 85.34
ONC: 52.17
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
ROIV: --

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): ROIV does not report P/E ratio, so it has no value marker; ONC is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

BeOne Medicines (ONC) at 7.04 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.04

Max: 58.18
Q3: 25.77
Median: 7.30
ONC: 7.04
Q1: 3.01
Min: 0.01

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV: 3,728.61
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both BeOne Medicines (ONC) at 7.98 and Roivant Sciences (ROIV) at 6.64 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.98

Max: 13.53
ONC: 7.98
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max: 13.53
ROIV: 6.64
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BeOne Medicines (ONC) vs. Roivant Sciences (ROIV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BeOne Medicines (ONC) and Roivant Sciences (ROIV)
Metric	ONC	ROIV
P/E Ratio (TTM)	52.17	--
P/S Ratio (TTM)	7.04	3,728.61
P/B Ratio (MRQ)	7.98	6.64
Free Cash Flow Yield (TTM)	2.21%	-3.98%